Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | TNF | P01375 | 3/20 | 0.45 |
| ▸ | TOP2A | P11388 | 2/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011233 | 0.99 | FAAH (0.50) | FAAHTNFTOP2ACTNNB1SMN1; SMN2 | |
| SCHEMBL4138665 | 0.99 | FAAH (0.50) | FAAHTNFTOP2ACTNNB1SMN1; SMN2 | |
| SCHEMBL4158992 | 0.97 | TNF (0.48) | FAAHTNFTOP2ACTNNB1SMN1; SMN2 | |
| SCHEMBL5617063 | 0.95 | FAAH (0.48) | FAAHTNFTOP2ACTNNB1SMN1; SMN2 | |
| SCHEMBL4143705 | 0.93 | SMN1; SMN2 (0.44) | TNFTOP2ASMN1; SMN2PDE5AMEN1 | |
| SCHEMBL5616925 | 0.91 | TLR7 (0.48) | FAAHTLR7 | |
| SCHEMBL5617118 | 0.91 | FAAH (0.48) | FAAHTLR7 | |
| SCHEMBL5617292 | 0.89 | FAAH (0.48) | FAAHTNFTOP2ACTNNB1PDE5A | |
| SCHEMBL5616929 | 0.88 | FAAH (0.49) | FAAHTNFTOP2ACTNNB1PDE5A | |
| SCHEMBL4151691 | 0.88 | HDAC6 (0.46) | SMN1; SMN2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-9328110-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| EP-1687307-B1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-8697873-B2 | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-04-15 | — | — | US | disclosed |
| EP-1687307-A4 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070072893-A1 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-29 | — | — | US | disclosed |
| EP-1730143-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1687307-A2 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M Innovative Properties Company (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005094531-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005051317-A2 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072893-A1 | Substituted imidazo ring systems and methods | IL2, IRF3, EIF2AK2 | FAAH 4468/4885TNF 39/4885TOP2A 679/4885 |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | FAAH 4579/4885TNF 50/4885TOP2A 810/4885 |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | IL2, IL4, IFNG | FAAH 2810/4885TNF 77/4885TOP2A 1258/4885 |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | FAAH 4579/4885TNF 50/4885TOP2A 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.